Sharemaestro company-news research for Regeneron Pharmaceuticals, Inc. (REGN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Provisional evidence
Company news sentiment
Latest REGN news and sentiment
Regeneron Pharmaceuticals, Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
17/100 evidence confidence
78% direct company focus
12 current stories across 1 publishers
Current company news
Early balanced news score
12 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone65/100
→
Published 30-day score51/100
Latest source headline
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)
finance.yahoo.com · 09 Sep 2026 14:51
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
12 current stories are mapped specifically to REGN.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.099.
Confidence is 17/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
17/100
Confidencethin evidence
78%/100
Company news12 company stories
93/100
Story agreement7/100 difference
News history
Daily score and story count over 30 days
18 Aug02 Sep16 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.099 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness15
recency-weighted evidenceAgreement93
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks12 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
20 Mar16 Jun11 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
11 Sep 202652MXN 13793.320313-3.5%
04 Sep 202653MXN 14288.780273+2.0%
28 Aug 202651MXN 14010.0-1.0%
21 Aug 202650MXN 14158.660156+3.7%
14 Aug 202644MXN 13653.05384+7.7%
07 Aug 202641MXN 12677.193766+0.0%
31 Jul 202643MXN 12677.268828+17.1%
24 Jul 202647MXN 10823.301754+0.0%
Provisional evidence
News subjects
What is shaping the score
Earnings617 stories · 58%
Regulatory and legal642 stories · 17%
Capital return591 stories · 8%
Deals and strategy501 stories · 8%
Market update501 stories · 8%
Source mix
Where the evidence comes from
finance.yahoo.com6111 stories · 92%
seekingalpha.com551 stories · 8%
Recurring subjects
Subjects appearing most often
Biotech12Fda Approval6Pharma4Earnings4Clinical Trials4Rare Diseases2Price Target2Healthcare2Balance Sheet2Valuation1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral13 Sep 23:07
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Sep 23:07 | 52 | -1 | 18/100 (-4) | 12 (-4) | Provisional |
| 09 Sep 23:59 | 53 | +0 | 22/100 (-1) | 16 (0) | Provisional |
| 08 Sep 23:59 | 53 | -1 | 23/100 (-9) | 16 (-14) | Provisional |
| 30 Aug 23:59 | 54 | +0 | 32/100 (+1) | 30 (-2) | Provisional |
| 29 Aug 23:59 | 54 | +4 | 31/100 (+1) | 32 (-11) | Provisional |
| 27 Aug 23:59 | 50 | +1 | 30/100 (+2) | 43 (-2) | Provisional |
| 25 Aug 23:59 | 49 | -1 | 28/100 (-8) | 45 (-3) | Provisional |
| 20 Aug 23:59 | 50 | +5 | 36/100 (+6) | 48 (+1) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
finance.yahoo.comDirect company coverageStored article
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)
American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the "American Century Investments Focused Dynamic Growth Fund". The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback in June as momentum waned and investors anticipated potential interest rate hikes by the Federal Reserve. Growth and AI stocks outperformed value stocks, while large-cap companies generally sur
BiotechEarningsEarnings GrowthHedge FundsPrice Target
- Published
- 09 Sep 2026 14:51
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.4d old
- Duplicates
- 1 consolidated
#259Tone
finance.yahoo.comDirect company coverageStored article
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
Harbor Funds, an investment management company, released its Q2 2026 investor letter for "Harbor Mid Cap Value Fund". The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence capital spending cycle. Small caps outperformed large caps, with the Russell 2000® gaining 21.5% compared to the Russell 1000's 15.1%. Growth stocks led within large caps, while Information Technology rose about 33%, contributing significantly to the
BiotechFinancialsHealthcarePrice TargetShare Buyback
- Published
- 08 Sep 2026 15:41
- News subject
- Capital return
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 40/100
- 30-day weight
- 33.3% of the score · 7.3d old
- Duplicates
- 1 consolidated
#364Tone
finance.yahoo.comDirect company coverageStored article
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View
Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a longer period, despite a slightly negative 3 year total shareholder return and a modest 5 year total sh
Balance SheetBiotechEarningsFda ApprovalPharmaRevenue Growth
- Published
- 30 Aug 2026 02:15
- News subject
- Earnings
- Why this score
- Positive valuation view, Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 41/100
- 30-day weight
- 14.3% of the score · 16.9d old
- Duplicates
- 1 consolidated
#476Tone
finance.yahoo.comDirect company coverageStored article
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP
Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare, which many investors explore further through 39 healthcare AI stocks.NasdaqGS:REGN Earnings & Revenue Growt
BiotechFda ApprovalPharmaRare Diseases
- Published
- 29 Aug 2026 20:14
- News subject
- Earnings
- Why this score
- Contract or approval won, Fda Approval, Business expansion
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 55/100
- 30-day weight
- 19.2% of the score · 17.2d old
- Duplicates
- 1 consolidated
#557Tone
finance.yahoo.comDirect company coverageStored article
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of new abnormal bone lesions by 94% compared with placebo. The decision completed an unusual clinical recovery. Regeneron paused an earlier study in 2020 after five patients died during its op
BiotechClinical TrialsFda ApprovalRare Diseases
- Published
- 27 Aug 2026 21:04
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 7% of the score · 19.1d old
- Duplicates
- 1 consolidated
#657Tone
finance.yahoo.comDirect company coverageStored article
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund's Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index's 13.87% and the S&P 500's 15.20% returns. Over three years, SSHFX and SSHVX posted annualized gains of 19.41% and 19.66%, outperforming the Russell Value (17.79%) but underperforming the S&P 500 (20.61%). The powerful rebound of stocks in the quarter was driven by strong pe
Balance SheetBiotechClinical TrialsEarningsEnergyFree Cash Flow
- Published
- 27 Aug 2026 12:43
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 5.9% of the score · 19.5d old
- Duplicates
- 1 consolidated
#7—Not directional
finance.yahoo.comDirect company coverageStored article
Veeva Vault CRM Selected by Regeneron
Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need. Veeva Vault CRM Selected by Regeneron "We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM,
BiotechCrmPharma
- Published
- 25 Aug 2026 11:03
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.5d old
- Duplicates
- 1 consolidated
#870Tone
finance.yahoo.comDirect company coverageStored article
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved Pasatru (garetosmab-grts) to reduce the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare genetic disorder characterized by progressive formation of abnormal bone within muscles, tendons, ligaments and other connective tissues, a process known as HO. Pasatru is a fully human monoclonal antibody derived using Regeneron's VelocImmune technology. It works by blocking Activin A, a protein discovered by Regene
BiotechFda ApprovalPharma
- Published
- 20 Aug 2026 14:36
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 46/100
- 30-day weight
- 13.3% of the score · 26.4d old
- Duplicates
- 1 consolidated
#972Tone
finance.yahoo.comDirect company coverageStored article
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron's portfolio, reinforcing the company's focus on specialized, high-complexity immunology therapies. We'll now examine how Pasatru's FOP approval, as an ultra-rare immunology therapy, could influence Regeneron's broader investment narrative. The best AI stocks today ma
BiotechFda ApprovalImmunologyOphthalmologyRare Disease
- Published
- 20 Aug 2026 05:10
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 4.1% of the score · 26.8d old
- Duplicates
- 1 consolidated
#1061Tone
finance.yahoo.comDirect company coverageStored article
Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has alread
BiotechClinical TrialsEarningsShare PriceSplitValuation
- Published
- 20 Aug 2026 04:28
- News subject
- Earnings
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 2.9% of the score · 26.8d old
- Duplicates
- 1 consolidated
#11—Not directional
finance.yahoo.comDirect company coverageStored article
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026 Morgan Stanley 24th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026 Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://
BiotechDrug DevelopmentHealthcare
- Published
- 19 Aug 2026 20:05
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.2d old
- Duplicates
- 1 consolidated
#12—Not directional
seekingalpha.comDirect company coverageStored article
Regeneron wins FDA nod for rare bone disorder therapy
[FDA Headquarters] * The U.S. Food and Drug Administration on Wednesday approved Pasatru, a treatment developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) for adults with an ultra-rare bone growth disorder known as fibrodysplasia ossificans progressiva. * Earlier this year, the regulator granted priority review for the company’s Biologics License Application for the treatment also known as garetosmab, setting a target action date in August. [https://seekingalpha.com/news/4553881-regeneron-wins-fda-review-rare-disease-therapy] * The BLA was supported by data from Regeneron’s (RE
BiotechClinical TrialsFda Approval
- Published
- 19 Aug 2026 17:53
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.3d old
- Duplicates
- 1 consolidated
Earlier company news
REGN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 61 older REGN headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to REGN, but the headline and available text are not mainly about Regeneron Pharmaceuticals, Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of REGN sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.